nach oben

Journal of Mammary Gland Biology and Neoplasia

Erschienen in:

01.12.2008

Role of Insulin-Like Growth Factor Binding Proteins in Mammary Gland Development

verfasst von: D. J. Flint, E. Tonner, J. Beattie, G. J. Allan

Erschienen in: Journal of Mammary Gland Biology and Neoplasia | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

Insulin-like growth factors (IGFs) play an important role in mammary gland development and their effects are, in turn, influenced by a family of 6 IGF-binding proteins (IGFBPs). The IGFBPs are expressed in time- and tissue-specific fashion during the periods of rapid growth and involution of the mammary gland. The precise roles of these proteins in vivo have, however, been difficult to determine. This review examines the indirect evidence (evolution, chromosomal location and roles in lower life-forms) the evidence from in vitro studies and the attempts to examine their roles in vivo, using IGFBP-deficient and over-expression models. Evidence exists for a role of the IGFBPs in inhibition of the survival effects of IGFs as well as in IGF-enhancing effects from in vitro studies. The location of the IGFBPs, often associated with the extracellular matrix, suggests roles as a reservoir of IGFs or as a potential barrier, restricting access of IGFs to distinct cellular compartments. We also discuss the relative importance of IGF-dependent versus IGF-independent effects. IGF-independent effects include nuclear localization, activation of proteases and interaction with a variety of extracellular matrix and cell surface proteins. Finally, we examine the increasing evidence for the IGFBPs to be considered as part of a larger family of extracellular matrix proteins involved in morphogenesis and tissue re-modeling.

Tonner E, Allan GJ, Flint DJ. Hormonal control of plasmin and tissue-type plasminogen activator activity in rat milk during involution of the mammary gland. J Endocrinol. 2000;167(2):265–73.PubMed

Wood TL, Richert MM, Stull MA, Allar MA. The insulin-like growth factors (IGFs) and IGF binding proteins in postnatal development of murine mammary glands. J Mammary Gland Biol Neoplasia. 2000;5(1):31–42.PubMed

Ruan W, Catanese V, Wieczorek R, Feldman M, Kleinberg DL. Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid. Endocrinology 1995;136(3):1296–302.PubMed

Kleinberg DL. Early mammary development: growth hormone and IGF-1. J Mammary Gland Biol Neoplasia. 1997;2(1):49–57.PubMed

Weber MS, Boyle PL, Corl BA, Wong EA, Gwazdauskas FC, Akers RM. Expression of ovine insulin-like growth factor-1 (IGF-1) stimulates alveolar bud development in mammary glands of transgenic mice. Endocrine 1998;8(3):251–9.PubMed

Bates P, Fisher R, Ward A, Richardson L, Hill DJ, Graham CF. Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). Br J Cancer. 1995;72(5):1189–93.PubMed

Flint DJ, Boutinaud M, Tonner E, Wilde CJ, Hurley W, Accorsi PA, et al. Insulin-like growth factor binding proteins initiate cell death and extracellular matrix remodeling in the mammary gland. Domest Anim Endocrinol. 2005;29(2):274–82.PubMed

Neuenschwander S, Schwartz A, Wood TL, Roberts CT Jr., Henninghausen L, LeRoith D. Involution of the lactating mammary gland is inhibited by the IGF system in a transgenic mouse model. J Clin Invest. 1996;97(10):2225–32.PubMed

Hadsell DL, Greenberg NM, Fligger JM, Baumrucker CR, Rosen JM. Targeted expression of des(1-3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression. Endocrinology 1996;137(1):321–30.PubMed

10.

Kleinberg DL, Feldman M, Ruan W. IGF-I: an essential factor in terminal end bud formation and ductal morphogenesis. J Mammary Gland Biol Neoplasia. 2000;5(1):7–17.PubMed

11.

Arai T, Parker A, Busby W Jr., Clemmons DR. Heparin, heparan sulfate, and dermatan sulfate regulate formation of the insulin-like growth factor-I and insulin-like growth factor-binding protein complexes. J Biol Chem. 1994;269(32):20388–93.PubMed

12.

Mohan S, Nakao Y, Honda Y, Landale E, Leser U, Dony C, et al. Studies on the mechanisms by which insulin-like growth factor (IGF) binding protein-4 (IGFBP-4) and IGFBP-5 modulate IGF actions in bone cells. J Biol Chem. 1995;270(35):20424–31.PubMed

13.

Flint DJ, Tonner E, Allan GJ. Insulin-like growth factor binding proteins: IGF-dependent and -independent effects in the mammary gland. J Mammary Gland Biol Neoplasia. 2000;5(1):65–73.PubMed

14.

Allar MA, Wood TL. Expression of the insulin-like growth factor binding proteins during postnatal development of the murine mammary gland. Endocrinology 2004;145(5):2467–77.PubMed

15.

Humphreys RC. Programmed cell death in the terminal endbud. J Mammary Gland Biol Neoplasia. 1999;4(2):213–20.PubMed

16.

Blatchford DR, Quarrie LH, Tonner E, McCarthy C, Flint DJ, Wilde CJ. Influence of microenvironment on mammary epithelial cell survival in primary culture. J Cell Physiol. 1999;181(2):304–11.PubMed

17.

Gouon-Evans V, Rothenberg ME, Pollard JW. Postnatal mammary gland development requires macrophages and eosinophils. Development 2000;127(11):2269–82.PubMed

18.

Tonner E, Barber MC, Travers MT, Logan A, Flint DJ. Hormonal control of insulin-like growth factor-binding protein-5 production in the involuting mammary gland of the rat. Endocrinology 1997;138(12):5101–7.PubMed

19.

Rosfjord EC, Dickson RB. Growth factors, apoptosis, and survival of mammary epithelial cells. J Mammary Gland Biol Neoplasia. 1999;4(2):229–37.PubMed

20.

Theil PK, Labouriau R, Sejrsen K, Thomsen B, Sorensen MT. Expression of genes involved in regulation of cell turnover during milk stasis and lactation rescue in sow mammary glands. J Anim Sci. 2005;83(10):2349–56.PubMed

21.

Norgaard JV, Theil PK, Sorensen MT, Sejrsen K. Cellular mechanisms in regulating mammary cell turnover during lactation and dry period in dairy cows. J Dairy Sci. 2008;91(6):2319–27.PubMed

22.

Brisken C, Ayyannan A, Nguyen C, Heineman A, Reinhardt F, Tan J, et al. IGF-2 is a mediator of prolactin-induced morphogenesis in the breast. Dev Cell. 2002;3(6):877–87.PubMed

23.

Hovey RC, Harris J, Hadsell DL, Lee AV, Ormandy CJ, Vonderhaar BK. Local insulin-like growth factor-II mediates prolactin-induced mammary gland development. Mol Endocrinol. 2003;17(3):460–71.PubMed

24.

Grimm SL, Seagroves TN, Kabotyanski EB, Hovey RC, Vonderhaar BK, Lydon JP, et al. Disruption of steroid and prolactin receptor patterning in the mammary gland correlates with a block in lobuloalveolar development. Mol Endocrinol. 2002;16(12):2675–91.PubMed

25.

Marshman E, Green KA, Flint DJ, White A, Streuli CH, Westwood M. Insulin-like growth factor binding protein 5 and apoptosis in mammary epithelial cells. J Cell Sci. 2003;116(Pt 4):675–82.PubMed

26.

Allan GJ, Tonner E, Barber MC, Travers MT, Shand JH, Vernon RG, et al. Growth hormone, acting in part through the insulin-like growth factor axis, rescues developmental, but not metabolic, activity in the mammary gland of mice expressing a single allele of the prolactin receptor. Endocrinology 2002;143(11):4310–9.PubMed

27.

Tonner E, Barber MC, Allan GJ, Beattie J, Webster J, Whitelaw CB, et al. Insulin-like growth factor binding protein-5 (IGFBP-5) induces premature cell death in the mammary glands of transgenic mice. Development 2002;129(19):4547–57.PubMed

28.

Ning Y, Hoang B, Schuller AG, Cominski TP, Hsu MS, Wood TL, et al. Delayed mammary gland involution in mice with mutation of the insulin-like growth factor binding protein 5 gene. Endocrinology 2007;148(5):2138–47.PubMed

29.

Silha JV, Murphy LJ. Insulin-like growth factor binding proteins in development. Adv Exp Med Biol. 2005;567:55–89.PubMed

30.

Pell JM, Salih DA, Cobb LJ, Tripathi G, Drozd A. The role of insulin-like growth factor binding proteins in development. Rev Endocr Metab Disord. 2005;6(3):189–98.PubMed

31.

Rotwein P, James PL, Kou K. Rapid activation of insulin-like growth factor binding protein-5 gene transcription during myoblast differentiation. Mol Endocrinol. 1995;9(7):913–23.PubMed

32.

Allan GJ, Flint DJ, Patel K. Insulin-like growth factor axis during embryonic development. Reproduction 2001;122(1):31–9.PubMed

33.

Allander SV, Coleman M, Luthman H, Powell DR. Chicken insulin-like growth factor binding protein (IGFBP)-5: conservation of IGFBP-5 structure and expression during evolution. Comp Biochem Physiol B Biochem Mol Biol. 1997;116(4):477–83.PubMed

34.

Krumlauf R. Hox genes in vertebrate development. Cell 1994;78(2):191–201.PubMed

35.

Ning Y, Schuller AG, Bradshaw S, Rotwein P, Ludwig T, Frystyk J, et al. Diminished growth and enhanced glucose metabolism in triple knockout mice containing mutations of insulin-like growth factor binding protein-3, -4, and -5. Mol Endocrinol. 2006;20(9):2173–86.PubMed

36.

Murali SG, Liu X, Nelson DW, Hull AK, Grahn M, Clayton MK, et al. Intestinotrophic effects of exogenous IGF-I are not diminished in IGF binding protein-5 knockout mice. Am J Physiol Regul Integr Comp Physiol. 2007;292(6):R2144–50.PubMed

37.

Ning Y, Schuller AG, Conover CA, Pintar JE. Insulin-like growth factor (IGF) binding protein-4 is both a positive and negative regulator of IGF activity in vivo. Mol Endocrinol. 2008;22(5):1213–25.PubMed

38.

Leu JI, Crissey MA, Craig LE, Taub R. Impaired hepatocyte DNA synthetic response posthepatectomy in insulin-like growth factor binding protein 1-deficient mice with defects in C/EBP beta and mitogen-activated protein kinase/extracellular signal-regulated kinase regulation. Mol Cell Biol. 2003;23(4):1251–9.PubMed

39.

DeMambro VE, Clemmons DR, Horton LG, Bouxsein ML, Wood TL, Beamer WG, et al. Gender-specific changes in bone turnover and skeletal architecture in igfbp-2-null mice. Endocrinology 2008;149(5):2051–61.PubMed

40.

Silha JV, Murphy LJ. Insights from insulin-like growth factor binding protein transgenic mice. Endocrinology 2002;143(10):3711–4.PubMed

41.

Wolf E, Schneider MR, Zhou R, Fisch TM, Herbach N, Dahlhoff M, et al. Functional consequences of IGFBP excess-lessons from transgenic mice. Pediatr Nephrol. 2005;20(3):269–78.PubMed

42.

Rajkumar K, Barron D, Lewitt MS, Murphy LJ. Growth retardation and hyperglycemia in insulin-like growth factor binding protein-1 transgenic mice. Endocrinology 1995;136(9):4029–34.PubMed

43.

Rajkumar K, Murphy LJ. Enhanced gluconeogenesis and hepatic insulin resistance in insulin-like growth factor binding protein-1 transgenic mice. Biochim Biophys Acta. 1999;1426(3):491–7.PubMed

44.

Gay E, Seurin D, Babajko S, Doublier S, Cazillis M, Binoux M. Liver-specific expression of human insulin-like growth factor binding protein-1 in transgenic mice: repercussions on reproduction, ante- and perinatal mortality and postnatal growth. Endocrinology 1997;138(7):2937–47.PubMed

45.

Hoeflich A, Fettscher O, Lahm H, Blum WF, Kolb HJ, Engelhardt D, et al. Overexpression of insulin-like growth factor-binding protein-2 results in increased tumorigenic potential in Y-1 adrenocortical tumor cells. Cancer Res. 2000;60(4):834–8.PubMed

46.

Silha JV, Sheppard PC, Mishra S, Gui Y, Schwartz J, Dodd JG, et al. Insulin-like growth factor (IGF) binding protein-3 attenuates prostate tumor growth by IGF-dependent and IGF-independent mechanisms. Endocrinology 2006;147(5):2112–21.PubMed

47.

Silha JV, Gui Y, Mishra S, Leckstrom A, Cohen P, Murphy LJ. Overexpression of gly56/gly80/gly81-mutant insulin-like growth factor-binding protein-3 in transgenic mice. Endocrinology 2005;146(3):1523–31.PubMed

48.

Zhang M, Smith EP, Kuroda H, Banach W, Chernausek SD, Fagin JA. Targeted expression of a protease-resistant IGFBP-4 mutant in smooth muscle of transgenic mice results in IGFBP-4 stabilization and smooth muscle hypotrophy. J Biol Chem. 2002;277(24):21285–90.PubMed

49.

Zhou R, Flaswinkel H, Schneider MR, Lahm H, Hoeflich A, Wanke R, et al. Insulin-like growth factor-binding protein-4 inhibits growth of the thymus in transgenic mice. J Mol Endocrinol. 2004;32(2):349–64.PubMed

50.

Salih DA, Tripathi G, Holding C, Szestak TA, Gonzalez MI, Carter EJ, et al. Insulin-like growth factor-binding protein 5 (Igfbp5) compromises survival, growth, muscle development, and fertility in mice. Proc Natl Acad Sci USA. 2004;101(12):4314–9.PubMed

51.

Salih DA, Mohan S, Kasukawa Y, Tripathi G, Lovett FA, Anderson NF, et al. Insulin-like growth factor-binding protein-5 induces a gender-related decrease in bone mineral density in transgenic mice. Endocrinology 2005;146(2):931–40.PubMed

52.

Bienvenu G, Seurin D, Grellier P, Froment P, Baudrimont M, Monget P, et al. Insulin-like growth factor binding protein-6 transgenic mice: postnatal growth, brain development, and reproduction abnormalities. Endocrinology 2004;145(5):2412–20.PubMed

53.

Bunn RC, Fowlkes JL. Insulin-like growth factor binding protein proteolysis. Trends Endocrinol Metab. 2003;14(4):176–81.PubMed

54.

Imai Y, Busby WH Jr., Smith CE, Clarke JB, Garmong AJ, Horwitz GD, et al. Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture. J Clin Invest. 1997;100(10):2596–605.PubMed

55.

Kajantie E, Dunkel L, Rutanen EM, Seppala M, Koistinen R, Sarnesto A, et al. IGF-I, IGF binding protein (IGFBP)-3, phosphoisoforms of IGFBP-1, and postnatal growth in very low birth weight infants. J Clin Endocrinol Metab. 2002;87(5):2171–9.PubMed

56.

Jones JI, Gockerman A, Busby WH Jr, Wright G, Clemmons DR. Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci USA. 1993;90(22):10553–7.PubMed

57.

Schedlich LJ, Le Page SL, Firth SM, Briggs LJ, Jans DA, Baxter RC. Nuclear import of insulin-like growth factor-binding protein-3 and -5 is mediated by the importin beta subunit. J Biol Chem. 2000;275(31):23462–70.PubMed

58.

Amaar YG, Thompson GR, Linkhart TA, Chen ST, Baylink DJ, Mohan S. Insulin-like growth factor-binding protein 5 (IGFBP-5) interacts with a four and a half LIM protein 2 (FHL2). J Biol Chem. 2002;277(14):12053–60.PubMed

59.

Xu Q, Li S, Zhao Y, Maures TJ, Yin P, Duan C. Evidence that IGF binding protein-5 functions as a ligand-independent transcriptional regulator in vascular smooth muscle cells. Circ Res. 2004;94(5):E46–54.PubMed

60.

Jurgeit A, Berlato C, Obrist P, Ploner C, Massoner P, Schmolzer J, et al. Insulin-like growth factor-binding protein-5 enters vesicular structures but not the nucleus. Traffic 2007;8(12):1815–28.PubMed

61.

Amaar YG, Baylink DJ, Mohan S. Ras-association domain family 1 protein, RASSF1C, is an IGFBP-5 binding partner and a potential regulator of osteoblast cell proliferation. J Bone Miner Res. 2005;20(8):1430–9.PubMed

62.

Leal SM, Liu Q, Huang SS, Huang JS. The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor. J Biol Chem. 1997;272(33):20572–6.PubMed

63.

Andress DL. Insulin-like growth factor-binding protein-5 (IGFBP-5) stimulates phosphorylation of the IGFBP-5 receptor. Am J Physiol. 1998;274(4 Pt 1):E744–50.PubMed

64.

Oh Y, Gucev Z, Ng L, Muller HL, Rosenfeld RG. Antiproliferative actions of insulin-like growth factor binding protein (IGFBP)-3 in human breast cancer cells. Prog Growth Factor Res. 1995;6(2–4):503–12.PubMed

65.

Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem. 1997;272(18):12181–8.PubMed

66.

Oh Y, Muller HL, Ng L, Rosenfeld RG. Transforming growth factor-beta-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor binding protein-3 action. J Biol Chem. 1995;270:13589–92.PubMed

67.

Leal SM, Huang SS, Huang JS. Interactions of high affinity insulin-like growth factor-binding proteins with the type V transforming growth factor-beta receptor in mink lung epithelial cells. J Biol Chem. 1999;274(10):6711–7.PubMed

68.

McCaig C, Perks CM, Holly JM. Intrinsic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin. J Cell Sci. 2002;115(Pt 22):4293–303.PubMed

69.

Lee KW, Liu B, Ma L, Li H, Bang P, Koeffler HP, et al. Cellular internalization of insulin-like growth factor binding protein-3: distinct endocytic pathways facilitate re-uptake and nuclear localization. J Biol Chem. 2004;279(1):469–76.PubMed

70.

Beattie J, Allan GJ, Lochrie JD, Flint DJ. Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis. Biochem J. 2006;395(1):1–19.PubMed

71.

Clemmons DR. Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol. 1998;140(1–2):19–24.PubMed

72.

Pilewski JM, Liu L, Henry AC, Knauer AV, Feghali-Bostwick CA. Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. Am J Pathol. 2005;166(2):399–407.PubMed

73.

Jones JI, Gockerman A, Busby WH Jr., Camacho-Hubner C, Clemmons DR. Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I. J Cell Biol. 1993;121(3):679–87.PubMed

74.

Liu B, Weinzimer SA, Gibson TB, Mascarenhas D, Cohen P. Type I alpha collagen is an IGFBP-3 binding protein. Growth Horm IGF Res. 2003;13(2–3):89–97.PubMed

75.

Nam TJ, Busby WH Jr., Clemmons DR. Human fibroblasts secrete a serine protease that cleaves insulin-like growth factor-binding protein-5. Endocrinology 1994;135(4):1385–91.PubMed

76.

Morales TI. The role and content of endogenous insulin-like growth factor-binding proteins in bovine articular cartilage. Arch Biochem Biophys. 1997;343(2):164–72.PubMed

77.

Firth SM, Baxter RC. The role of glycosylation in the action of IGFBP-3. Prog Growth Factor Res. 1995;6(2–4):223–9.PubMed

78.

Sorrell AM, Shand JH, Tonner E, Gamberoni M, Accorsi PA, Beattie J, et al. Insulin-like growth factor-binding protein-5 activates plasminogen by interaction with tissue plasminogen activator, independently of its ability to bind to plasminogen activator inhibitor-1, insulin-like growth factor-I, or heparin. J Biol Chem. 2006;281(16):10883–9.PubMed

79.

Inoki I, Shiomi T, Hashimoto G, Enomoto H, Nakamura H, Makino K, et al. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J. 2002;16(2):219–21.PubMed

80.

Abreu JG, Ketpura NI, Reversade B, De Robertis EM. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol. 2002;4(8):599–604.PubMed

81.

Nguyen TQ, Goldschmeding R. Bone morphogenetic protein-7 and connective tissue growth factor: novel targets for treatment of renal fibrosis? Pharm Res. 2008;25:2416–26.PubMed

82.

Honegger B, Galic M, Kohler K, Wittwer F, Brogiolo W, Hafen E, et al. Imp-L2, a putative homolog of vertebrate IGF-binding protein 7, counteracts insulin signaling in Drosophila and is essential for starvation resistance. J Biol. 2008;7(3):10.PubMed

83.

Alic N, Partridge L. Stage debut for the elusive Drosophila insulin-like growth factor binding protein. J Biol. 2008;7(6):18.PubMed

84.

Nam TJ, Busby WH Jr., Rees C, Clemmons DR. Thrombospondin and osteopontin bind to insulin-like growth factor (IGF)-binding protein-5 leading to an alteration in IGF-I-stimulated cell growth. Endocrinology 2000;141(3):1100–6.PubMed

85.

Clemmons DR, Busby WH, Arai T, Nam TJ, Clarke JB, Jones JI, et al. Role of insulin-like growth factor binding proteins in the control of IGF actions. Prog Growth Factor Res. 1995;6(2–4):357–66.PubMed

86.

Hampel B, Fortschegger K, Ressler S, Chang MW, Unterluggauer H, Breitwieser A, et al. Increased expression of extracellular proteins as a hallmark of human endothelial cell in vitro senescence. Exp Gerontol. 2006;41(5):474–81.PubMed

87.

Yoon IK, Kim HK, Kim YK, Song IH, Kim W, Kim S, et al. Exploration of replicative senescence-associated genes in human dermal fibroblasts by cDNA microarray technology. Exp Gerontol. 2004;39(9):1369–78.PubMed

88.

Kim KS, Seu YB, Baek SH, Kim MJ, Kim KJ, Kim JH, et al. Induction of cellular senescence by insulin-like growth factor binding protein-5 through a p53-dependent mechanism. Mol Biol Cell. 2007;18(11):4543–52.PubMed

89.

Beausejour CM, Krtolica A, Galimi F, Narita M, Lowe SW, Yaswen P, et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J. 2003;22(16):4212–22.PubMed

90.

Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005;120(4):513–22.PubMed

91.

Kenyon C. A conserved regulatory system for aging. Cell 2001;105(2):165–8.PubMed

92.

Longo VD, Finch CE. Evolutionary medicine: from dwarf model systems to healthy centenarians? Science 2003;299(5611):1342–6.PubMed

93.

Chakravarthy MV, Abraha TW, Schwartz RJ, Fiorotto ML, Booth FW. Insulin-like growth factor-I extends in vitro replicative life span of skeletal muscle satellite cells by enhancing G1/S cell cycle progression via the activation of phosphatidylinositol 3′-kinase/Akt signaling pathway. J Biol Chem. 2000;275(46):35942–52.PubMed

94.

Shimokawa I, Higami Y, Tsuchiya T, Otani H, Komatsu T, Chiba T, et al. Life span extension by reduction of the growth hormone-insulin-like growth factor-1 axis: relation to caloric restriction. FASEB J. 2003;17(9):1108–9.PubMed

95.

Shimokawa I, Higami Y, Utsuyama M, Tuchiya T, Komatsu T, Chiba T, et al. Life span extension by reduction in growth hormone-insulin-like growth factor-1 axis in a transgenic rat model. Am J Pathol. 2002;160(6):2259–65.PubMed

96.

Holzenberger M. The GH/IGF-I axis and longevity. Eur J Endocrinol. 2004;151(Suppl 1):S23–27.PubMed

97.

Holzenberger M, Dupont J, Ducos B, Leneuve P, Geloen A, Even PC, et al. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 2003;421(6919):182–7.PubMed

98.

Giudice LC, Irwin JC, Dsupin BA, Pannier EM, Jin IH, Vu TH, et al. Insulin-like growth factor (IGF), IGF binding protein (IGFBP), and IGF receptor gene expression and IGFBP synthesis in human uterine leiomyomata. Hum Reprod. 1993;8(11):1796–806.PubMed

99.

Hossenlopp P, Segovia B, Lassarre C, Roghani M, Bredon M, Binoux M. Evidence of enzymatic degradation of insulin-like growth factor-binding proteins in the 150 K complex during pregnancy. J Clin Endocrinol Metab. 1990;71(4):797–805.PubMed

100.

Davenport ML, Clemmons DR, Miles MV, Camacho-Hubner C, D’Ercole AJ, Underwood LE. Regulation of serum insulin-like growth factor-I (IGF-I) and IGF binding proteins during rat pregnancy. Endocrinology 1990;127(3):1278–86.PubMedCrossRef

101.

Fielder PJ, Thordarson G, English A, Rosenfeld RG, Talamantes F. Expression of a lactogen-dependent insulin-like growth factor-binding protein in cultured mouse mammary epithelial cells. Endocrinology 1992;131(1):261–7.PubMed

102.

Claussen M, Zapf J, Braulke T. Proteolysis of insulin-like growth factor binding protein-5 by pregnancy serum and amniotic fluid. Endocrinology 1994;134(4):1964–6.PubMed

103.

Lee KO, Oh Y, Giudice LC, Cohen P, Peehl DM, Rosenfeld RG. Identification of insulin-like growth factor-binding protein-3 (IGFBP-3) fragments and IGFBP-5 proteolytic activity in human seminal plasma: a comparison of normal and vasectomized patients. J Clin Endocrinol Metab. 1994;79(5):1367–72.PubMed

104.

Xu S, Cwyfan-Hughes SC, van der Stappen JW, Sansom J, Burton JL, Donnelly M, et al. Altered insulin-like growth factor-II (IGF-II) level and IGF-binding protein-3 (IGFBP-3) protease activity in interstitial fluid taken from the skin lesion of psoriasis. J Invest Dermatol. 1996;106(1):109–12.PubMed

105.

Xu S, Savage P, Burton JL, Sansom J, Holly JM. Proteolysis of insulin-like growth factor-binding protein-3 by human skin keratinocytes in culture in comparison to that in skin interstitial fluid: the role and regulation of components of the plasmin system. J Clin Endocrinol Metab. 1997;82(6):1863–8.PubMed

106.

Hadsell DL, Bonnette SG. IGF and insulin action in the mammary gland: lessons from transgenic and knockout models. J Mammary Gland Biol Neoplasia. 2000;5(1):19–30.PubMed

Titel: Role of Insulin-Like Growth Factor Binding Proteins in Mammary Gland Development
verfasst von: D. J. Flint
E. Tonner
J. Beattie
G. J. Allan
Publikationsdatum: 01.12.2008
Verlag: Springer US
Erschienen in: Journal of Mammary Gland Biology and Neoplasia / Ausgabe 4/2008
Print ISSN: 1083-3021
Elektronische ISSN: 1573-7039
DOI: https://doi.org/10.1007/s10911-008-9095-3

Springer Medizin

Role of Insulin-Like Growth Factor Binding Proteins in Mammary Gland Development

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2008

IGF Binding Proteins (IGFBPs) and Regulation of Breast Cancer Biology

IGF-I, GH, and Sex Steroid Effects in Normal Mammary Gland Development

IGF and Insulin Receptor Signaling in Breast Cancer

Insulin Receptor Substrates (IRSs) and Breast Tumorigenesis

The Impact of Transgenic IGF-IR Overexpression on Mammary Development and Tumorigenesis

The IGF System in Mammary Development and Breast Cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie